Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Stephen Salloway(Providence College), Karen Smirnakis(Biogen (United States)), Spyros Chalkias(Moderna Therapeutics (United States)), Derk D. Purcell(BioClinica (United States)), Patrick Burkett(Biogen (United States)), Joyce Suhy(BioClinica (United States)), Samantha Budd Haeberlein(Biogen (United States)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Priya Singhal(Jaypee Institute of Information Technology), Fiona Forrestal(Biogen (United States)), Jerome Barakos(California Pacific Medical Center), Guanfang Wang(Cytel (United States)), Ying Tian(Biogen (United States)), Kimberly Umans(Biogen (United States))
Cited by 590
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k